Swedish Orphan Biovitrum AB's EBIT per Share for the
three
months ended in Mar. 2026 was $0.57.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.42.
During the past 12 months, the average EBIT per Share Growth Rate of Swedish Orphan Biovitrum AB was -76.00% per year.
During the past 3 years, the average EBIT per Share Growth Rate was -40.00% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -19.40% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 15.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Swedish Orphan Biovitrum AB's EBIT per Share or its related term are showing as below:
BIOVF'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -55.6 Med: 10.1 Max: 382.7
Current: -40
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Swedish Orphan Biovitrum AB was 382.70% per year. The lowest was -55.60% per year. And the median was 10.10% per year.
BIOVF's 3-Year EBIT Growth Rate is ranked worse than 92.59% of 810
companies
in the Drug Manufacturers industry
Industry Median: 7.5
vs BIOVF: -40.00
Swedish Orphan Biovitrum AB (OTCPK:BIOVF) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Swedish Orphan Biovitrum AB EBIT per Share Related Terms
Swedish Orphan Biovitrum AB EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.42
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Swedish Orphan Biovitrum AB (BIOVF) has a EBIT per Share of $0.42 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Swedish Orphan Biovitrum AB and its competitors. According to the industry distribution chart, Swedish Orphan Biovitrum AB ranks #750 out of 810 companies in the Drug Manufacturers industry, placing it in the top 92.6%.
Is Swedish Orphan Biovitrum AB's EBIT per Share too high?
Swedish Orphan Biovitrum AB's current EBIT per Share is $0.42. The Drug Manufacturers industry median EBIT per Share is 7.50. Swedish Orphan Biovitrum AB's value of $0.42 is 94.4% below this industry median. Based on the distribution chart, Swedish Orphan Biovitrum AB ranks #750 out of 810 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Swedish Orphan Biovitrum AB has a GF Score™ of 83/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Swedish Orphan Biovitrum AB's EBIT per Share compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Swedish Orphan Biovitrum AB ranks #750 out of 810 companies for EBIT per Share. This places Swedish Orphan Biovitrum AB in the lower half of its industry. The industry median EBIT per Share is 7.50. Swedish Orphan Biovitrum AB's value of $0.42 is 94.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.50, based on 810 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Swedish Orphan Biovitrum AB's current EBIT per Share of $0.42 is 94.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Swedish Orphan Biovitrum AB and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Swedish Orphan Biovitrum AB's current EBIT per Share is $0.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Swedish Orphan Biovitrum AB stock overvalued right now?
Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB (BIOVF) is currently considered Significantly Overvalued. The stock's GF Value™ is $34.89, compared to a current price of $49.03 — trading 40.5% above its estimated fair value. The current EBIT per Share is $0.42 and 94.4% below the Drug Manufacturers industry median of 7.50. Swedish Orphan Biovitrum AB's overall GF Score™ is 83/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Swedish Orphan Biovitrum AB (BIOVF), the current EBIT per Share is $0.42 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Swedish Orphan Biovitrum AB (BIOVF) Overvalued in 2026?
Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB stock appears to be overvalued.
The current stock price of $49.03 is trading 40.5% above its estimated GF Value™ of $34.89.
GuruFocus considers Swedish Orphan Biovitrum AB to be Significantly Overvalued.
Key valuation signals for BIOVF:
EBIT per Share: $0.42
GF Value™: $34.89 vs. price of $49.03 (40.5% above fair value)
Industry Position: 94.4% below the Drug Manufacturers median (#750 of 810)
No single metric tells the full story. See the BIOVF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drugs, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).
83GF Score
Get the complete analysis for BIOVF
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BIOVF has been successfully added to your 
